Project Name: ASCVD Primary Care Lipid Management Collaborative Working Project

Project Summary:

The CWP will be led by a Clinical Pharmacist alongside a multi-disciplinary team; including Pharmacy Technician, Healthcare Assistant, Administrative Support, General Practitioner providing clinical oversight aiming to achieve:

  1. Identification of sub-optimally treated patients who are not achieving recommended targets for lipid management  
  2. Identification of patients who have previously not tolerated or refused alternative lipid modification therapies  
  3. Review of treatment options and decision on next steps in collaboration with patients  
  4. Counsel and optimise patients where appropriate  
  5. Early identification of at-risk patients who have not had intervention in their health and wellbeing 
  6. Identification of patients, following risk assessment review, of patients who are sub-optimally treated  

Planned Milestones:

  1. PCN Level Lipid Management pathway/protocol development. Clinical Audit and Clinical Audit Discussion with Member Practices.
  2. Collection of baseline data, in line with the measures of success contained within the Data Collection table above
  3. Collection & submission of 3 months clinical activity data.Project Review meeting to discuss project progress.
  4. Collection & submission of 6 months clinical activity data. Project Review meeting to discuss project progress.
  5. Collection & submission of 9 months clinical activity data. Project Review meeting to discuss project progress.
  6. Collection & submission of 12 months clinical activity data. Project Review meeting to discuss project progress.
  7. Development of Business Case and Poster
  8. Analysis of CWP data, submission of Final CWP Report, Submission of Outcomes Summary

Expected Benefits:

Anticipated benefits for Patients

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.
  • Enhanced experience around ASCVD with ongoing management of the condition.  
  • Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events 
  • The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up. Thus, levelling health inequalities within the PCN. 

Anticipated Benefits for Granta PCN

  • Increased proportion of ASCVD patients reviewed by primary care  
  • Increased proportion of ASCVD patients receiving expert and timely review closer to home 
  • Reduction in ASCVD referral rates to secondary care 
  • Increased proportion of patients receiving guideline-directed pharmacotherapy 
  • Insight into benefits of primary care pharmacist led lipid management clinics in primary care  
  • Support aligned to NHS Long Term Plan, CVDPREVENT, and Network Contract DES

Anticipated Benefits for Novartis

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine 
  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life by supporting high quality Collaborative Working with healthcare organisation which addresses the problem of health inequalities 
  • Ethical, professional, and transparent relationship between Novartis and healthcare organisation

Start Date & Duration: February 2023 for 16 months